

# Anthony J Mutsaers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6207456/publications.pdf>

Version: 2024-02-01

51  
papers

2,192  
citations

318942

23  
h-index

252626

46  
g-index

52  
all docs

52  
docs citations

52  
times ranked

3188  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of lymphocyte-specific programmed cell death protein 1 receptor expression and cytokines in blood and urine in canine urothelial carcinoma patients. <i>Veterinary and Comparative Oncology</i> , 2022, 20, 427-436.	0.8	4
2	Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines. <i>Veterinary Immunology and Immunopathology</i> , 2022, 243, 110367.	0.5	10
3	Modulation of mTOR signaling by radiation and rapamycin treatment in canine mast cell cancer cells.. <i>Canadian Journal of Veterinary Research</i> , 2022, 86, 3-12.	0.2	0
4	Plasma 25-hydroxyvitamin D and the inflammatory response in canine cancer. <i>Veterinary and Comparative Oncology</i> , 2021, 19, 232-241.	0.8	4
5	Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs. <i>Clinical Cancer Research</i> , 2021, 27, 3005-3016.	3.2	26
6	Combination therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells. <i>PLoS ONE</i> , 2021, 16, e0255591.	1.1	13
7	Using a Prime-Boost Vaccination Strategy That Proved Effective for High Resolution Epitope Mapping to Characterize the Elusive Immunogenicity of Survivin. <i>Cancers</i> , 2021, 13, 6270.	1.7	0
8	Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells. <i>BMC Veterinary Research</i> , 2021, 17, 382.	0.7	6
9	Companion canines: an under-utilised model to aid in translating anti-metastatics to the clinic. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 7-12.	1.7	3
10	Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy. <i>Veterinary and Comparative Oncology</i> , 2020, 18, 559-569.	0.8	16
11	Unconventional diets and nutritional supplements are more common in dogs with cancer compared to healthy dogs: An online global survey of 345 dog owners. <i>Veterinary and Comparative Oncology</i> , 2020, 18, 706-717.	0.8	8
12	Effect of timing of bisphosphonate administration on canine osteosarcoma cells undergoing radiation therapy. <i>Canadian Journal of Veterinary Research</i> , 2020, 84, 225-229.	0.2	0
13	Flow Cytometric Detection of Circulating Osteosarcoma Cells in Dogs. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 997-1007.	1.1	8
14	Osteosarcoma in the Post Genome Era: Preclinical Models and Approaches to Identify Tractable Therapeutic Targets. <i>Current Osteoporosis Reports</i> , 2019, 17, 343-352.	1.5	15
15	Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation. <i>Pharmaceutics</i> , 2019, 11, 179.	2.0	35
16	MicroRNA profiling in canine multicentric lymphoma. <i>PLoS ONE</i> , 2019, 14, e0226357.	1.1	27
17	Effects of the potassium-sparing diuretic amiloride on chemotherapy response in canine osteosarcoma cells. <i>Journal of Veterinary Internal Medicine</i> , 2019, 33, 800-811.	0.6	9
18	Evaluation of effects of radiation therapy combined with either pamidronate or zoledronate on canine osteosarcoma cells. <i>Canadian Journal of Veterinary Research</i> , 2019, 83, 3-10.	0.2	3

#	ARTICLE	IF	CITATIONS
19	In vitro evaluation of a simulated pneumoperitoneum environment using carbon dioxide on canine transitional cell carcinoma. <i>Veterinary Surgery</i> , 2018, 47, 412-420.	0.5	3
20	Synthesis of curcumin-functionalized gold nanoparticles and cytotoxicity studies in human prostate cancer cell line. <i>Applied Nanoscience (Switzerland)</i> , 2018, 8, 347-357.	1.6	44
21	Murine models of osteosarcoma: A piece of the translational puzzle. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 4241-4250.	1.2	16
22	The autophagy inhibitor spautin-1, either alone or combined with doxorubicin, decreases cell survival and colony formation in canine appendicular osteosarcoma cells. <i>PLoS ONE</i> , 2018, 13, e0206427.	1.1	29
23	Evaluation of metronomic cyclophosphamide chemotherapy as maintenance treatment for dogs with appendicular osteosarcoma following limb amputation and carboplatin chemotherapy. <i>Journal of the American Veterinary Medical Association</i> , 2018, 252, 1377-1383.	0.2	17
24	Antihistaminic and cardiorespiratory effects of diphenhydramine hydrochloride in anesthetized dogs undergoing excision of mast cell tumors. <i>Journal of the American Veterinary Medical Association</i> , 2017, 251, 804-813.	0.2	10
25	Enhancing Immune Responses to Cancer Vaccines Using Multi-Site Injections. <i>Scientific Reports</i> , 2017, 7, 8322.	1.6	18
26	Adjuvant Doxorubicin with or without Metronomic Cyclophosphamide for Canine Splenic Hemangiosarcoma. <i>Journal of the American Animal Hospital Association</i> , 2017, 53, 304-312.	0.5	27
27	Evaluation of toxicity of a chronic alternate day metronomic cyclophosphamide chemotherapy protocol in dogs with naturally occurring cancer. <i>Canadian Veterinary Journal</i> , 2017, 58, 51-55.	0.0	10
28	Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma. <i>Canadian Veterinary Journal</i> , 2017, 58, 1059-1064.	0.0	14
29	Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells. <i>BMC Veterinary Research</i> , 2016, 12, 82.	0.7	22
30	Comparison of serum cytokine levels between dogs with multicentric lymphoma and healthy dogs. <i>Veterinary Immunology and Immunopathology</i> , 2016, 182, 106-114.	0.5	36
31	Targeting HSP70 and GRP78 in canine osteosarcoma cells in combination with doxorubicin chemotherapy. <i>Cell Stress and Chaperones</i> , 2016, 21, 1065-1076.	1.2	23
32	The DNA Helicase Recq14 Is Required for Normal Osteoblast Expansion and Osteosarcoma Formation. <i>PLoS Genetics</i> , 2015, 11, e1005160.	1.5	34
33	Preclinical mouse models of osteosarcoma. <i>BoneKEy Reports</i> , 2015, 4, 670.	2.7	32
34	Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. <i>Clinical Cancer Research</i> , 2015, 21, 3216-3229.	3.2	58
35	Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?. <i>Bone</i> , 2014, 62, 56-63.	1.4	166
36	Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA. <i>Bone</i> , 2013, 55, 166-178.	1.4	65

#	ARTICLE	IF	CITATIONS
37	Genetically engineered mouse models and human osteosarcoma. <i>Clinical Sarcoma Research</i> , 2012, 2, 19.	2.3	33
38	Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2. <i>MAbs</i> , 2010, 2, 199-208.	2.6	57
39	Dose-Dependent Increases in Circulating TGF- $\beta$ and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent. <i>Clinical Cancer Research</i> , 2009, 15, 2397-2405.	3.2	38
40	Metronomic Chemotherapy. <i>Topics in Companion Animal Medicine</i> , 2009, 24, 137-143.	0.4	39
41	Vascular Endothelial Growth Factor-mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth. <i>Cancer Research</i> , 2008, 68, 521-529.	0.4	108
42	Chemotherapy: New Uses for Old Drugs. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2007, 37, 1079-1090.	0.5	15
43	Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17069-17074.	3.3	360
44	Positive-Contrast Imaging in the Rabbit Hind-Limb of Transplanted Cells Bearing Endocytosed Superparamagnetic Beads. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2006, 8, 817-823.	1.6	18
45	Treatment of eight dogs with nasal tumours with alternating doses of doxorubicin and carboplatin in conjunction with oral piroxicam. <i>Australian Veterinary Journal</i> , 2004, 82, 676-680.	0.5	55
46	Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. <i>Journal of the American Veterinary Medical Association</i> , 2004, 224, 388-394.	0.2	113
47	Canine Transitional Cell Carcinoma. <i>Journal of Veterinary Internal Medicine</i> , 2003, 17, 136-144.	0.6	186
48	Canine transitional cell carcinoma. <i>Journal of Veterinary Internal Medicine</i> , 2003, 17, 136-44.	0.6	100
49	Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 183-8.	1.9	58
50	Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs. <i>Journal of the American Veterinary Medical Association</i> , 2002, 220, 1813-1817.	0.2	52
51	Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. <i>Cancer Research</i> , 2002, 62, 356-8.	0.4	149